SCHEMBL31532076

SCHEMBL31532076

CCNc1ncc2cc(Br)c(=O)[nH]c2n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK4 P11802 1/20 0.42
▸ CCND1 P24385 1/20 0.42
▸ CCND2 P30279 1/20 0.42
▸ CCND3 P30281 1/20 0.42
▸ ALDH1A1 P00352 12/20 0.40
▸ HSD17B10 Q99714 12/20 0.40
▸ CYP1A2 P05177 11/20 0.40
▸ CASP1 P29466 11/20 0.40
▸ CASP7 P55210 11/20 0.40
▸ GLA P06280 9/20 0.40
▸ USP2 O75604 6/20 0.40
▸ HPGD P15428 3/20 0.40
▸ CYP2C19 P33261 2/20 0.40
▸ IGF1R P08069 1/20 0.39
▸ CLK4 Q9HAZ1 6/20 0.39
▸ MEN1 O00255 4/20 0.39
▸ KMT2A Q03164 4/20 0.39
▸ MAPK1 P28482 4/20 0.39
▸ TSHR P16473 4/20 0.39
▸ CYP2D6 P10635 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31532055 0.83 SIK2 (0.45) MAPK1EGFRFGFR1
SCHEMBL22612785 0.83 SIK2 (0.45) MAPK1EGFRFGFR1
SCHEMBL31532117 0.79 CDK4 (0.40) CDK4CCND1CCND2CCND3ALDH1A1
SCHEMBL23632980 0.77 DYRK1A (0.35) HSD17B10MAT2A
SCHEMBL29838035 0.77 DYRK1A (0.35) HSD17B10MAT2A
SCHEMBL29861753 0.76 PDK2 (0.39) CLK4MAPK1FGFR1
SCHEMBL1899374 0.75 ALDH1A1 (0.55) ALDH1A1HSD17B10CYP1A2CASP1CASP7
SCHEMBL31532080 0.75 MAPK14 (0.47) CDK4CCND1CCND2CCND3ALDH1A1
SCHEMBL255621 0.75 MEN1 (0.46) CDK4CCND1CCND2CCND3ALDH1A1
SCHEMBL15280148 0.74 CDC7 (0.38) ALDH1A1HSD17B10GLACLK4FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025043349-A1 PYRIMIDOPYRIDONE AND PTERIDONE DERIVATIVES AS INHIBITORS OF THE GCN2 KINASE, COMPOSITIONS AND USES THEREOF ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2025-03-06 — — WO disclosed
Send feedback